X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The trial tests BetterLife’s proprietary inhaled interferon alpha-2b product, AP-003 administered via nebulizer. AP-003, being a Type I interferon, is a broad acting antiviral agent used in COVID-19 patients.
Lead Product(s): Interferon Alfa-2B
Therapeutic Area: Infections and Infectious Diseases Product Name: AP-003
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pontificia Universidad Catolica de Chile
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2021
Details:
The IFN-a2b treatment arms will receive BetterLife’s proprietary inhaled IFN-a2b product, AP-003, administered via nebulizer, twice daily for 10 days.
Lead Product(s): Interferon Alfa-2B
Therapeutic Area: Infections and Infectious Diseases Product Name: AP-003
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: BetterLife Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2021
Details:
Altum Pharmaceuticals has entered into a Letter of Intent with Pontificia Universidad Católica de Chile to conduct a randomized placebo-controlled trial (“IN2COVID”) in COVID-19 patients testing Altum’s proprietary inhaled interferon alpha-2b product, AP-003.
Lead Product(s): Interferon Alfa-2B
Therapeutic Area: Infections and Infectious Diseases Product Name: AP-003
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2021
Details:
Altum reports that in May 2020 management requested a pre-IND meeting with the FDA with the intent to discuss the planned development of AP-003 (Interferon Alpha-2b for inhalation) for the treatment of COVID-19.
Lead Product(s): Interferon a2b
Therapeutic Area: Infections and Infectious Diseases Product Name: AP-003
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BetterLife Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 27, 2020
Details:
BetterLife has amended terms of the agreement entered into on May 6, 2020 with Altum to acquire worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell AP-003, a potential COVID-19 treatment.
Lead Product(s): AntiCovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BetterLife Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 11, 2020
Details:
BetterLife has secured lock-up agreements from shareholders of Altum Pharmaceuticals Inc. representing 67.12% of the outstanding common shares of Altum. BetterLife and Altum entered collaboration to to commercialize and sell AP-003 for COVID-19.
Lead Product(s): AntiCovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BetterLife Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 04, 2020
Details:
BetterLife Pharma has been worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell AntiCovir, a COVID-19 treatment, from Altum Pharmaceuticals Inc.
Lead Product(s): AntiCovir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BetterLife Pharma
Deal Size: $20.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement May 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
